Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
暂无分享,去创建一个
E. Perez | Y. Chia | J. Hamm | A. Awada | G. Jerusalem | P. Barrett-Lee | V. Cocquyt | R. Coleman | M. Huizing | A. Hannah | U. Hoch | Agustin A. Garcia | K. Sideras | S. O'Reilly | A. Mehdi | D. Young | Carol Zhao | S. Chan | S. O’Reilly
[1] J. Lubiński,et al. Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Harvey,et al. Breast cancer—facts and figures , 2013 .
[3] M. Borad,et al. A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors , 2012, Clinical Cancer Research.
[4] Chris Twelves,et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study , 2011, The Lancet.
[5] R. Paridaens,et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] H. Iwata,et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer , 2010, Breast Cancer Research and Treatment.
[7] E. Perez,et al. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer , 2010, Breast Cancer Research and Treatment.
[8] J. Jassem,et al. Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2009, European journal of cancer.
[9] Eric Sauerbrei,et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] D. V. Hoff,et al. 8015 NKTR-102 demonstrates nonclinical and phase 1 clinical anti-tumor activity in ovarian cancer , 2009 .
[11] David A. Smith,et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Sparano,et al. Ixabepilone plus capecitabine improves progression free survival in patients with metastatic breast cancer resistant to taxanes: a pooled analysis from two phase III trials. , 2009 .
[13] M. Borad,et al. 595 POSTER First Phase I trial of NKTR-102 (PEG-irinotecan) reveals early evidence of broad anti-tumor activity in three schedules , 2008 .
[14] M. Eldon,et al. NKTR-102, a novel PEGylated-irinotecan, has a superior acute safety and tolerability profile compared to irinotecan in rats and dogs , 2008 .
[15] H. Rugo,et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] N. Robert,et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. , 2007, Clinical breast cancer.
[17] M. Bentley,et al. Polyethylene glycol conjugation of irinotecan improves its antitumor activity in three mouse xenograft models , 2007 .
[18] M. Bentley,et al. 727 POSTER PEGylation governs the disposition and metabolism of irinotecan following administration of a novel PEG–Irinotecan conjugate , 2007 .
[19] M. Bentley,et al. 722 POSTER Antitumor activity and pharmacokinetics of a novel PEGylated irinotecan in irinotecan-resistant colorectal tumours implanted in mice , 2007 .
[20] S. Steinberg,et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Baselga,et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] E. Perez,et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] D. Richel,et al. A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer , 2004, British Journal of Cancer.
[24] E. Perez,et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[26] E. Perez,et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.